Effect of primary anthracycline-based chemotherapy on disseminated tumor cells in locally advanced breast cancer

被引:0
|
作者
Jäger, C [1 ]
Kafka, A [1 ]
Bossert, S [1 ]
Grundmann, R [1 ]
Windisch, J [1 ]
Kreienberg, R [1 ]
Heilmann, V [1 ]
机构
[1] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany
关键词
breast cancer; disseminated tumor cells; anthracycline-based; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The leading cause of death from epithelial cancer is metastatic tumor relapse due to early dissemination of tumor cells. In this study we investigated the elimination rate of disseminated tumor cells in bone marrow and the clinical response under primary chemotherapy in locally advanced breast cancer. Patients and Methods: Thirty patients underwent primary anthracycline-containing chemotherapy for breast cancer. For immunocytochemical tumor cell detection in bone marrow, the monoclonal antibody 5D3 was used. Results: At time of diagnosis, 10/30 (33%) patients had cytokeratin-positive tumor cells in bone marrow. After primary and chemotherapy, 8/30 (27%) patients still tested positive. Clinical complete response (cCR) was observed in 5/30 (17%) patients partial response (cPR) in 12/30 (40%) patients, resulting in an overall rate of clinical response to primary chemotherapy in 57%. Conclusion: Primary chemotherapy in breast cancer is effective regarding the reduction of tumor size but seems incapable of reducing the burden of disseminated tumor cells in bone marrow.
引用
收藏
页码:3209 / 3214
页数:6
相关论文
共 50 条
  • [31] Cisplatin and paclitaxel for treatment of patients with advanced or metastatic breast cancer, previously treated with anthracycline-based chemotherapy
    Munarriz, A
    Oltra, A
    Santaballa, A
    Segura, A
    Pastor, M
    Montalar, J
    Herranz, C
    10TH INTERNATIONAL CONGRESS ON SENOLOGY - BREAST DISEASES OF THE SENOLOGIC INTERNATIONAL SOCIETY, 1998, : 765 - 768
  • [32] HER-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a Mexican population of locally advanced breast cancer patients
    Muñoz-Gonzalez, D
    Zeichner-Gancz, I
    Candelaria, M
    Ramirez-Ugalde, MT
    Perez-Sanchez, M
    Cervantes-Vazquez, G
    Cantu-de Leon, D
    Mora-Tizcareño, A
    Leonor-Ortíz, J
    MEDICAL ONCOLOGY, 2005, 22 (01) : 23 - 28
  • [33] Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome
    Ozmen, V
    Cabioglu, N
    Dolay, K
    Bilir, A
    Kecer, M
    Aydiner, A
    Muslumanoglu, M
    Igci, A
    Bozfakioglu, Y
    Dagoglu, T
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 68 (02) : 147 - 157
  • [34] Topoisomerase II-α amplification as potential predictive marker of complete response to anthracycline-based chemotherapy in locally advanced/metastatic breast cancer.
    Cardoso, F
    Durbecq, V
    Bernard-Marty, C
    Rouas, G
    Leroy, JY
    Max, M
    Giuliani, R
    Larsimont, D
    Jacobson, K
    Piccart, MJ
    Di Leo, A
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S64 - S64
  • [35] HER-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a Mexican Population of locally advanced breast cancer patients
    David Muñoz-Gonzalez
    Isabel Zeichner-Gancz
    Myrna Candelaria
    Maria Teresa Ramirez-Ugalde
    Manuel Perez-Sanchez
    Guadalupe Cervantes-Vazquez
    David Cantu-de Leon
    Arcelia Mora-Tizcareño
    Julio Leonor-Ortíz
    Medical Oncology, 2005, 22 : 23 - 28
  • [36] The relationship between the difference neutrophil to lymphocyte ratio before and after anthracycline-based neoadjuvant chemotherapy with clinical response in locally advanced breast cancer
    Rahman, Hadian
    Ali, Iskandar
    Susilo, Dwi Hari
    BALI MEDICAL JOURNAL, 2023, 12 (03) : 3088 - 3092
  • [37] Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome
    Vahit Ozmen
    Neslihan Cabioglu
    Kemal Dolay
    Ayhan Bilir
    Mustafa Kecer
    Adnan Aydiner
    Mahmut Muslumanoglu
    Abdullah Igci
    Yavuz Bozfakioglu
    Temel Dagoglu
    Breast Cancer Research and Treatment, 2001, 68 : 147 - 157
  • [38] Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma
    Ferreri, AJM
    Campo, E
    Arnbrosetti, A
    Ilariucci, F
    Seymour, JF
    Willemze, R
    Arrigoni, G
    Rossi, G
    López-Guillermo, A
    Berti, E
    Eriksson, M
    Federico, M
    Cortelazzo, S
    Govi, S
    Frungillo, N
    Dell'Oro, S
    Lestani, M
    Asioli, S
    Pedrinis, E
    Ungari, M
    Motta, T
    Rossi, R
    Artusi, T
    Iuzzolino, P
    Zucca, E
    Cavalli, F
    Ponzoni, M
    ANNALS OF ONCOLOGY, 2004, 15 (08) : 1215 - 1221
  • [39] Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer
    Takala, Laura
    Barlund, Maarit
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Pirkko, Liisa
    ANTICANCER RESEARCH, 2019, 39 (01) : 279 - 283
  • [40] Late-onset cardiotoxicity in Anthracycline-based chemotherapy for breast cancer patients
    Mata Caballero, R.
    Serrano Antolin, J. M.
    Gonzalez Garcia, I. A.
    Muniz Garcia, J.
    Curcio Ruigomez, A.
    Gutierrez Landaluce, C.
    Morales Garcia, L. J.
    Del Castillo Arrojo, S.
    Guerra Martinez, J. A.
    Graupner Abad, C.
    Jimenez Hernandez, R. M.
    Cristobal Varela, C.
    Malon Gimenez, D.
    Talavera Calle, P.
    Alonso Martin, J. J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 118 - 119